12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO, CA
Other Events
Reg. FD
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Investor Presentation
Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre‑NDA Meeting
Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Announces the Appointment of Dan Weng, M.D., to Board of Directors
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
RW
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Definitive Merger Proxy Statement
PRER14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload